Evidence map›Paper›PMID 41510118›Full record

ArticleTranslational cancer research2025

A novel prognostic and immune-related biomarker

Kun Xia, Hong-Chao Zhu, Fang-Ye Lai, Zi-Hao Li, Wei Wang, Nan Wang

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kun XiaDalian University, Dalian, China.
Hong-Chao ZhuDalian University, Dalian, China.
Fang-Ye LaiDalian University, Dalian, China.
Zi-Hao LiDalian University, Dalian, China.
Wei WangDalian University, Dalian, China.
Nan WangDepartment of General Surgery, Dalian University Affiliated Xinhua Hospital, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: An aberrant expression of the voltage-gated potassium (Kv) channel family has been verified in a variety of tumors, which can contribute to tumor proliferation and migration by regulating the cell cycle, suppressing apoptosis, facilitating the epithelial-mesenchymal transition (EMT), and activating downstream tumor-associated pathways. Kv3.3 is encoded by the Kv channel subfamily C member 3 ( Methods: This study was conducted to investigate the differential expression, prognostic value, immune microenvironment (IME) signature, and biological functions of Results: The expression of Conclusions:

Indexed as

immune microenvironment (IME)KCNC3pan-cancer analysisprognosis

Identifiers

PMID41510118
PMCPMC12776232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.